AI Article Synopsis
- BRCA1- and BRCA2-mutated cancers respond well to PARP inhibitors, prompting researchers to explore other factors influencing this response.
- The study focused on the Fanconi anemia (FA) pathway, which is linked to DNA repair mechanisms, to identify additional predictors of sensitivity to PARP inhibitors.
- Variability in PARP inhibitor sensitivity was observed among different FANCD1/BRCA2-deficient cell lines, with DNA helicases FANCM and DDX11 emerging as key factors affecting treatment response.
Article Abstract
The encouraging response rates of BRCA1- and BRCA2-mutated cancers toward PARP inhibitors make it worthwhile to identify other potential determinants of PARP inhibitor responsiveness. Since the Fanconi anemia (FA) pathway coordinates several DNA repair pathways, including homologous recombination in which BRCA1 and BRCA2 play important roles, we investigated whether this pathway harbors other predictors of PARP inhibitor sensitivity. Lymphoblastoid cell lines derived from individuals with FA or clinically related syndromes, such as Warsaw breakage syndrome, were tested for PARP inhibitor sensitivity. Remarkably, we found a strong variability in PARP inhibitor sensitivity among different FANCD1/BRCA2-deficient lymphoblasts, suggesting that PARP inhibitor response depends on the type of FANCD1/BRCA2 mutation. We identified the DNA helicases FANCM and DDX11 as determinants of PARP inhibitor response. These results may extend the utility of PARP inhibition as effective anticancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dnarep.2014.12.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma.
BMC Cancer
December 2024
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Background: There is increasing interest in enhancing the response of the PARP inhibitor olaparib, which is currently approved for pancreatic ductal adenocarcinoma (PDAC) patients with defects in DNA damage repair associated with germline BRCA1/2 mutations. Moreover, agents that can mimic these defects in the absence of germline BRCA1/2 mutations are an area of active research in hopes of increasing the number of patients eligible for treatment with PARP inhibitors. The extent to which regorafenib, an FDA-approved tyrosine kinase inhibitor, can be used to enhance the efficacy of PARP inhibitors in PDAC cells without known BRCA1/2 mutations remains to be investigated.
View Article and Find Full Text PDFBreast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors.
NPJ Precis Oncol
December 2024
Institute of Systems, Molecular and Integrative Biology, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Understanding the genomic landscape of breast cancer brain metastases (BCBMs) is key to developing targeted treatments. In this study, targetable genomic profiling was performed on 822 BCBMs, 11,988 local breast cancer (BC) biopsies and 15,516 non-central nervous system (N-CNS) metastases (all unpaired samples) collected during the course of routine clinical care by Foundation Medicine Inc (Boston, MA). Clinically relevant genomic alterations were significantly enriched in BCBMs compared to local BCs and N-CNS metastases.
View Article and Find Full Text PDFNSC-3852 synergistically enhances the cytotoxicity of olaparib in oral squamous cell carcinoma.
Biochem Biophys Res Commun
December 2024
Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, 8-1 Kuzuhahanazono-cho, Hirakata, Osaka 573-1121, Japan. Electronic address:
The PARP inhibitor olaparib is an anti-cancer agent based on synthetic lethality that targets poly (ADP-ribose) polymerases. It is used as a therapeutic agent for breast, ovarian, pancreatic, and prostate cancers carrying BRCA1/2 mutations that cause deficiency in homologous recombination. In recent years, acquired resistance to PARP inhibitors has become a clinical problem in PARP inhibitor-treated patients.
View Article and Find Full Text PDFHematopoietic adverse events associated with PARP Inhibitors:A FAERS database study.
Expert Opin Drug Saf
December 2024
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University.
Article Synopsis
- The study aimed to identify and analyze hematopoietic adverse drug reactions (ADRs) linked to four PARP inhibitors: Olaparib, Niraparib, Rucaparib, and Talazoparib, using data from the FDA's FAERS database.
- Methodology involved data extraction from 2019 to 2024, applying standardized medical terminology to screen ADR signals using various statistical methods.
- Results showed that hematopoietic reactions mainly occurred within 30 days of treatment, with Niraparib presenting the highest adverse events, indicating the need for careful monitoring and individualized treatment plans for patient safety.
Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2.
Eur J Med Res
December 2024
Department of Immunology and Microbiology, College of Life Science and Technology, MOE Key Laboratory of Tumor Molecular Biology, Jinan University, No. 601 Huangpu Avenue West, Tianhe, Guangzhou, 510632, China.
Background: The T790M mutation in the epidermal growth factor receptor (EGFR) gene is the primary cause of resistance to EGFR-tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC) patients. Previous research demonstrated that certain traditional Chinese medicine (TCM) monomers exhibit anti-tumor effects against various malignancies. This study aims to investigate the potentials of shikonin screened from a TCM monomer library containing 1060 monomers in killing EGFR-T790M drug-resistant NSCLC cells and elucidate the underlying mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!